Volume 30 1973

Psycho—pharmacologia

Managing Editors

J. O. Cole M. Hamilton E. Jacobsen C. Kornetsky R. W. Russell

Editorial Board

D. Bovet, Sassari J. O. Cole, Boston J. Delay, Paris J. Elkes, Baltimore
M. Hamilton, Leeds H. Isbell, Lexington E. Jacobsen, København
M. E. Jarvik, Los Angeles S. S. Kety, Boston C. Kornetsky, Boston
R. W. Russell, Bedford Park M. Shepherd, London Hannah Steinberg, London
E. Strömgren, Risskov A. Wikler, Lexington

Advisory Board

M. Adler, Philadelphia N.-E. Anden, Göteborg J. Angst, Zürich J. B. Appel, Columbia, SC
S. Barondes, La Jolla A. M. Barrett, Leeds H. Barry III, Pittsburgh H. Blaschko, Oxford
D. Booth, Birmingham H. Brill, New York A. Carlsson, Göteborg
P. Carlton, New Brunswick C. K. Connors, Boston P. B. Dews, Boston
A. DiMascio, Boston E. Domino, Ann Arbor J. C. Eccles, Buffalo
U. S. von Euler, Stockholm A. Fessard, Paris M. Fink, New York
S. Fisher, Boston R. Fog, Roskilde S. Garattini, Milano S. Gershon, New York
S. C. Goldberg, Chevy Chase S. Grossman, Chicago L.-M. Gunne, Uppsala
H. Hanson, West Point J. Harvey, Iowa City H. E. Hill, Lexington
R. Hinde, Cambridge H. Hippius, München L. E. Hollister, Palo Alto
O. Hornykiewicz, Toronto E. Hosoya, Tokyo R. P. Hullin, Leeds S. Irwin, Portland
J. Jaffe, Washington W. Janke, Düsseldorf R. Jewett, Atlanta
R. T. Jones, San Francisco M. Jouvet, Lyon C. R. B. Joyce, Basel D. Joyce, London
M. Katz, Chevy Chase R. Kelleher, Boston K. F. Killam, Davis
G. Klerman, Boston N. S. Kline, Orangeburg M. H. Lader, London I. P. Lapin, Leningrad
L. Lasagna, Rochester V. Laties, Rochester A. Latz, Tel-Aviv
O. Lingjærde, Tromsø R. Lipman, Rockville A. Lubin, San Diego E. Marley, London
W. R. Martin, Lexington J. L. McGaugh, Irvine D. E. McMillan, Chapel Hill
N. Mello, Washington A. Mirsky, Boston C. Niemegeers, Beerse
S. Norton, Kansas City D. Overton, Philadelphia G. Pampiglione, London P. Pichot, Paris
R. W. Pickens, Minneapolis A. Randrup, Roskilde D. Richter, Epsom K. Rickels, Philadelphia
R. Rodnight, London J. M. Rose, Leeds R. T. Rubin, Los Angeles J. Scheel-Krüger, Roskilde
J. Schildkraut, Boston C. Schuster, Chicago C. Shagass, Philadelphia
P. Silverman, Macclesfield, Ches. F. Sjöqvist, Stockholm J. R. Smythies, Edinburgh
F. Sulser, Nashville R. Taber, Bloomfield T. Thompson, Minneapolis S. Udenfriend, Bethesda
H. Weil-Malherbe, Washington A. Weissman, Groton, CT T. Yanagita, Kawasaki
E. Zaimis, London O. Zangwill, Cambridge

Springer-Verlag
Berlin Heidelberg New York

The exclusive copyright for all languages and countries, including the right for photomechanical and any other reproductions, also in microform, is transferred to the publishers.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Springer-Verlag Berlin Heidelberg New York

Printed in Germany by Wiesbadener Graphische Betriebe GmbH, Wiesbaden

© by Springer-Verlag Berlin Heidelberg 1973

Contents

Subject Index VI

Agué, C.: Smoking Patterns, Nicotine Intake at Different Times of Day and Changes in Two Cardiovascular Variables while Smoking Cigarettes . . . 135
Agué, C.: Nicotine and Smoking: Effects upon Subjective Changes in Mood . 323
Angrist, B., Gershon, S.: Behavioral Profile of a Potent New Psychotoxic Compound 109

Ballinger, B. R., see Turnbull, M. J. 103
Beaton, J. M., see Webster, C. D., *et al.* 217
Berner, W., see Konzett, H., *et al.* 75
Bonnem, E. M., see Vogel, W. H., *et al.* 145

Carlsson, A., Magnusson, T., Svensson, T. H., Waldeck, B.: Effect of Ethanol on the Metabolism of Brain Catecholamines. 27
Charap, A. D., see Glick, S. D. 343
Chemerinski, E., see Fabian, H. E. M., *et al.* 369
Cherkin, A., see Riege, W. H. 195
Cohen, M. J., see Rickles, W. H., Jr., *et al.* 349
Connelly, J. F., Connelly, J. M., Epps, J. O.: Disruption of Dissociated Learning in a Discrimination Paradigm by Emotionally-Important Stimuli . . 275
Connelly, J. M., see Connelly, J. F., *et al.* 275
Craves, F. B., see Hitzemann, R. J., *et al.* 227

DiMascio, A.: The Effects of Benzodiazepines on Aggression: Reduced or Increased? 95
Domino, E. F., see Hitzemann, R. J., *et al.* 227
Dubinsky, B., see Goldberg, M. E., *et al.* 173
Duncan, S., see Powell, D. A., *et al.* 303

Epps, J. O., see Connelly, J. F., *et al.* 275
Evans, B. D., see Vogel, W. H., *et al.* 145

Fabian, H. E. M., Chemerinski, E., Merlo, A. B., Izquierdo, J. A.: Effect of Propranolol on Free Fatty Acids of Mice Plasma during a Passive Avoidance Test 369
Fink, R., see Stolerman, I. P., *et al.* 329
Fischer, J. F., see Vogel, W. H., *et al.* 145

Gauron, E. F., Rowley, V. N.: Effects on Offspring Behavior of Parental Early Drug Experience and Cross-Fostering 269
Gershon, S., see Angrist, B. 109
Gibbins, R. J., see LeBlanc, A. E., *et al.* 117
Glick, S. D., Charap, A. D.: Morphine Dependence in Rats with Medial Forebrain Bundle Lesions 343
Goldberg, M. E., Hefner, M. A., Robichaud, R. C., Dubinsky, B.: Effects of Δ^9-Tetrahydrocannabinol (THC) and Chlordiazepoxide (CDP) on State-Dependent Learning: Evidence for Asymmetrical Dissociation 173

Hasegawa, Y., Ibuka, N., Iwahara, S.: Effects of Chlordiazepoxide upon Successive Red-Green Discrimination Responses in Japanese Monkeys, *Macaca fuscata* 89
Hefner, M. A., see Goldberg, M. E., *et al.* 173
Henriksson, B. G., see Järbe, T. U. C. 315
Hitzemann, R. J., Loh, H. H., Craves, F. B., Domino, E. F.: The Use of *d*-Amphetamine Pellet Implantation as a Model for *d*-Amphetamine Tolerance in the Mouse 227

Holley, J. R., see Powell, D. A., *et al.* 303
Hruska, R. E., see Thut, P. D., *et al.* 355

Ibuka, N., see Hasegawa, Y., *et al.* 89
Iwahara, S., see Hasegawa, Y., *et al.* 89
Izquierdo, J. A., see Fabian, H. E. M., *et al.* 369

Järbe, T. U. C., Henriksson, B. G.: Acute Effects of Two Tetrahydrocannabinols (Δ^9-THC and Δ^8-THC) on Water Intake in Water Deprived Rats: Implications for Behavioral Studies on Marijuana Compounds 315
Jarvik, M. E., see Stolerman, I. P., *et al.* 329
Jones, B. E., Prada, J. A.: Relapse to Morphine Use in Dog 1

Kalant, H., see LeBlanc, A. E., *et al.* 117
Kelter, A., see Thut, P. D., *et al.* 355
Khavari, K. A., Risner, M. E.: Concentration-Ingestion Relations of Morphine-Adulterated Food and Morphine Solution 45
Khavari, K. A., Risner, M. E.: Opiate Dependence Produced by ad libitum Drinking of Morphine in Water, Saline, and Sucrose Vehicles 291
Konzett, H., Berner, W., Lochs, H.: Emotionally Induced Cardiovascular Changes in Man as a Means for the Investigation of Tranquillizing Drugs . 75
Knobloch, L. C., see Sofia, R. D. 185

LeBlanc, A. E., Gibbins, R. J., Kalant, H.: Behavioral Augmentation of Tolerance to Ethanol in the Rat 117
LeBlanc, A. E., see Webster, C. D., *et al.* 217
Lindell, T. J., see Thut, P. D., *et al.* 355
Lochs, H., see Konzett, H., *et al.* 75
Loh, H. H., see Hitzemann, R. J., *et al.* 227

Magnusson, T., see Carlsson, A., *et al.* 27
Marshman, J. A., see Webster, C. D., *et al.* 217
Martin, W. R., see Vaupel, D. B. 13
McIntyre, K. E., see Rickles, W. H., Jr., *et al.* 349
McKearney, J. W.: Effects of Methamphetamine and Chlordiazepoxide on Schedule-Controlled and Adjunctive Licking in the Rat 375
McLaughlin, J. C., see Vogel, W. H., *et al.* 145
McMillan, D. E.: Drugs and Punished Responding. III. Punishment Intensity as a Determinant of Drug Effect 61
Merlo, A. B., see Fabian, H. E. M., *et al.* 369
Mills, A. W., see Pick Cassens, G. 283
Mizne, J., see Thut, P. D., *et al.* 355
Modigh, K.: Effects of L-Tryptophan on Motor Activity in Mice 123

Niemegeers, C. J. E., see Wauquier, A. 163

Pick Cassens, G., Mills, A. W.: Lithium and Amphetamine: Opposite Effects on Threshold of Intracranial Reinforcement 283
Powell, D. A., Walters, K., Duncan, S., Holley, J. R.: The Effects of Chlorpromazine and *d*-Amphetamine upon Shock-Elicited Aggression 303
Prada, J. A., see Jones, B. E. 1

Rickles, W. H., Jr., Cohen, M. J., Whitaker, C. A., McIntyre, K. E.: Marijuana Induced State-Dependent Verbal Learning 349
Riege, W. H., Cherkin, A.: Retroactive Facilitation of Memory in Goldfish by Flurothyl 195
Risner, M. E., see Khavari, K. A. 45, 291
Robichaud, R. C., see Goldberg, M. E., *et al.* 173
Rowley, V. N., see Gauron, E. F. 269

Sandoval, R. G., Wang, R. I. H.: Characteristics of Pentazocine Dependence in Hospitalized Patients after Naloxone Administration 205
Saper, C. B., Sweeney, D. C.: Enhanced Appetitive Discrimination Learning in Rats Treated with α-Methyltyrosine 37

Smith, D. F., Smith, H. B.: The Effect of Prolonged Lithium Administration on Activity, Reactivity, and Endurance in the Rat 83
Smith, H. B., see Smith, D. F. 83
Sofia, R. D., Knobloch, L. C.: The Interaction of Δ^9-Tetrahydrocannabinol Pretreatment with Various Sedative-Hypnotic Drugs 185
Speiser, Z., see Weinstock, M. 241
Stolerman, I. P., Fink, R., Jarvik, M. E.: Acute and Chronic Tolerance to Nicotine Measured by Activity in Rats. 329
Svensson, T. H., see Carlsson, A., *et al.* 27
Sweeney, D. C., see Saper, C. B. 37

Thut, P. D., Hruska, R. E., Kelter, A., Mizne, J., Lindell, T. J.: The Effect of α-Amanitin on Passive and Active Avoidance Acquisition in Mice. . . 355
Trost, R. C.: Differential Classical Conditioning of Abstinence Syndrome in Morphine-Dependent Rats 153
Turnbull, M. J., Ballinger, B. R.: Urinary Excretion of Monoamines and Metabolites in Patients Dependent on and Withdrawn from Barbiturates 103

Vaupel, D. B., Martin, W. R.: Interaction of Oxotremorine with Atropine, Chlorpromazine, Cyproheptadine, Imipramine and Phenoxybenzamine on the Flexor Reflex of the Chronic Spinal Dog 13
Vogel, W. H., Evans, B. D., Bonnem, E. M., Fischer, J. F., McLaughlin, J. L.: Macromerine, Normacromerine and Bisnormacromerine: Non-Psychoactive Methylated Derivatives of Norepinephrine 145

Waldeck, B., see Carlsson, A., *et al.* 27
Walters, K., see Powell, D. A., *et al.* 303
Wang, R. I. H., see Sandoval, R. G. 205
Wauquier, A., Niemegeers, C. J. E.: Intracranial Self-Stimulation in Rats as a Function of Various Stimulus Parameters. III. Influence of Apomorphine on Medical Forebrain Bundle Stimulation with Monopolar Electrodes . . 163
Webster, C. D., LeBlanc, A. E., Marshman, J. A., Beaton, J. M.: Acquisition and Loss of Tolerance to l-Δ^9-trans-Tetrahydrocannabinol in Rats on an Avoidance Schedule 217
Weinstock, M., Speiser, Z.: The Effect of *dl*-Propranolol, *d*-Propranolol and Practolol on the Hyperactivity Induced in Rats by Prolonged Isolation . 241
Whitaker, C. A., see Rickles, W. H., Jr., *et al.* 349
Wray, S. R.: Possible Catecholamine Mediation of Levallorphan-Induced Behavioural Disruption in Rats 251
Wray, S. R.: Interaction of Stress and Psychotomimetic Drug-Action: Possible Implication for Psychosis 263

Indexed in Current Contents

Subject Index

A

Acquisition 173
Activation 135, 303
Activity 83, 227, 329
Adjunctive behavior 375
Aggression 95, 303
Agonistic behavior 303
α-Amantin 355
Amnesia 195
Amphetamines 1, 227, 283, 303
Animals 95
Apomorphine 163
Appetitive discrimination 37
—, motives, conditioned 153
Arousal 303
Atropine 13
Avoidance 251
—, active 355
—, conditioning 269
—, passive 355, 369

B

Barbituary dependence 103
Behavior 117
Benzodiazepines 95
Bisnormacromerine 145
Body weight 315
Brain stimulation, self 163, 283

C

Carbon dioxide 195
Catecholamines 27, 37, 103, 227, 251
Chlordiazepoxide 89, 173, 275, 375
Chlorpromazine 61, 303
Cholinergic mechanisms 13
Chronic spinal dog 13
Circadean rhythms 135
—, influence 303
Classical conditioning 153
Conditioned avoidance response 37, 45
Convulsions 195
Cross-fostering 269
Cross-generational drug effects 269

D

Dependence, drug 1, 45, 205
—, morphine 291, 343
Developmental psychopharmacology 269
Diastolic blood pressure 75
Diazepam 61
Disinhibition 89
Dissociated learning 275
Dogs 1, 13
Drinking 375
Drug interactions 185

E

Emotionality 275
Emotional stress 75
Endurance 83
Escape learning 275
Ethanol 27, 117
Exploratory activity 227

F

Flexor reflex 13
Flurothyl 195
Food intake 315
Foot shock 369
Forearm blood flow 75
Free fatty acids 369

G

Goldfish 195
Go/No-Go type discrimination 89

H

Heart rate 75, 135
Human subjects 75, 95, 103, 109, 135, 205, 323, 349
5-Hydroxyindole-3-acetic acid 103
5-Hydroxytryptamine 123
Hyperactivity 241

I

Implantation 227
Induction time 185
Ingestion 291
Interoceptive cues 153
Isolated rats 241

K

Kynurenines 123

L

Levallorphan 251
Licking 375
Lithium 83, 283
Locomotor 227
L-tryptophan 123

M

Macromerine 145
Marihuana 173, 185, 217, 315, 349
Medial forebrain bundle 163, 343

Memory 195, 355
Mental arithmetic 75
Mesoridazine 75
Metabolites 103
Methamphetamine 375
Methylated derivatives of norepinephrine 145
α-Methyltyrosine 37
Mice 27, 123, 173, 185, 227, 355, 369
Monkeys 89
Monamines 103
—, oxidase 27
Monopolar electrodes 163
Mood 323
Morphine 1, 45, 61, 53, 291, 343
—, addiction 343
—, drinking, eating 45
—, withdrawal 153, 343
Motor activity 123

N

Naloxone 205
Narcotic antagonist 251
Nicotine 135, 303, 329
Norepinephrine, derivatives of 145

O

One-trial learning 195
Operant conditioning 263
Oxotremorine 13

P

Pellet 227
Pentazocine 205
Pentobarbitol 61
Performance test 75
Physiological disposition 145
Pigeons 61
Practolol 241
Preference 45, 291
Propranolol 241, 369
Psychopharmacological indexes 135
Psychophysics 283
Psychotomimetic 109, 251, 263
Punishment intensity 61

R

Rate dependency 61
Rats 37, 45, 83, 117, 145, 153, 163, 217, 241, 251, 263, 269, 275, 283, 291, 303, 315, 329, 343, 375
Reactivity 83
Reinforcement 283
Relapse 1
Righting reflex, loss of 185
RNA polymerase 355

S

Saline 291
Schedule-controlled behavior 375
Sedative-hypnotic drugs 185
Seld-administration 1
—, rating 323
—, stimulation 163, 283
Shock-elicited behavior 303
Skin temperature 135
Sleeping time 185
Smoking habit 135, 323
Spinal cord 13
State-dependent learning 173, 349
Stereotypy 251
Stimulus parameter combinations, various 163
Stress 263
Stroop test 75
Sucrose 291
Systolic blood pressure 75

T

Temperature 195
THC 173, 185, 217, 315, 349
Thebaine analog 109
Thioridazine 75
Tolerance 117, 227, 329
Tranquillizer 75, 89
Transfer 275
Trifluoperazine effects 269
Tryptamine 123
L-Tryptophan 123
Turnover 27

U

Urinary amines 103

V

Verbal learning 349
Vocalization 315

W

Water-morphine solution 291
—, intake 315

Instructions to Authors

1. Papers will be published in **English, French or German.**

2. Authors should submit **manuscripts together with two copies.** The original illustration material (original drawings etc.) and two copies should be submitted together with the manuscript.

3. The text should be as **clear and concise** as possible. Both form and content of the paper should be carefully checked to exclude the need for corrections in proof. A charge will be made for changes introduced after the manuscript has been set in type.

4. **Manuscripts** should be typewritten, double-spaced, on one side of letter size paper and with wider margin on the left. The author should mark in the margin where figures and tables may be inserted. All pages should be numbered consecutively. Tables, footnotes and legends for illustrations should be typed (double-spaced) on separate pages. Use the metric system for text and figures.

5. The **first page** should bear:
the title; the name(s) of the author(s); the name of the laboratory where the work was carried out; a running title of not more than 67 typewriter strokes; footnotes to the title (marked by asterisks).

6. Each paper should be preceded by a brief **abstract** in English concerned with the methods used and with the experimental results which should be presented in such a way that it is possible for the reader to assess their significance. It should be as short as possible and should **not exceed 200 words.**
French and German articles should also have an **English translation of the title.**

7. Immediately following the abstract, some relevant **key words** should be supplied for subject indexing.

8. Articles dealing with **original investigations** should first state the problem concisely and arrange the material under Methods, Results, Discussion, References.

9. **Footnotes** should be kept to a minimum and numbered consecutively throughout the paper. Footnotes referring to the heading of the article are to be marked by asterisks.

10. The **bibliography** should include only work cited in the text. References should be listed alphabetically at the end of the paper as follows: *journal papers*—names and initials of all authors, full title, journal abbreviated in accordance with World Medical Periodicals, volume number, first and last page numbers, year in parentheses; *books*—names of authors, full title, edition, place, publisher, year. *Examples:*

Latz, A., Bain, G. T., Kornetsky, C.: Attenuated effect of chlorpromazine on conditioned avoidance as a function of rapid acquisition. Psychopharmacologia (Berl.) **14**, 23—32 (1960).

Fisher, S., Cole, J. O., Rickels, K., Uhlenhuth, E. H.: Drug set interaction: The effect of expectation on drug response in outpatients. In: Neuropsychopharmacology. Bradley, P. B., Flugle, F., and Hoch, P., eds., vol. 3, pp. 140—156. Amsterdam: Elsevier 1964.

Several publications by the same author or group of authors should be listed in chronological order; those that appear in the same year should be distinguished by the suffixes a, b, c etc. Citations in the text should be given in parentheses, e.g. (Beckman, 1958; Brown, 1963), except when the author's name is part of a sentence, e.g. "Man (1966) reported that . . ." When a paper with more than two authors is cited, all authors are named the first time, but subsequently only the first authors, e.g. (Miller *et al.*, 1963).

11. Figures should be separated from the text and numbered. They should be restricted to a minimum. Descriptions in captions should not be expanded in the text, nor should the same data be given in both graph and table form. Coloured or previously published illustrations are not usually accepted. Original drawings and graphs should be drawn in Indian ink with lines of uniform thickness. Where possible, **figures should be grouped,** bearing in mind maximum display area is 108×177 mm ($4^1/_4 \times 7''$). In general it should be assumed that the same degree of reduction will apply to all figures in the same paper. Inscriptions should allow for any reduction in scale—a capital letter should be about 1.8 mm high in the final version. If figures have to be redrawn for the block-maker, this may cause considerable delay in publication. Photographs should be sharp, well-contrasted glossy prints at right angles. Authors should mark them with Letraset (Instant Lettering).

CURRENT CONTENTS® CLINICAL PRACTICE

A NEW SERVICE THAT MAKES CONTINUING MEDICAL EDUCATION EASIER

When it comes to patient care, you know you've got to stay on top of what's new. But with busy-schedules giving less time for reading, it's easy to miss key journal articles relevant to your work. *Current Contents/Clinical Practice* is an easy way to keep up with what's being published.



Each week—in an easy-to-scan, pocket-sized format, *CC®/CP* will bring you reproduced *tables of contents* from 700 of the world's most important clinical journals. By spending less than an hour with *CC/CP*—it's ideal for browsing between rounds and work-ups—you'll efficiently organize your reading. No need to handle a single journal until you're ready to read the articles you've preselected by examining titles on contents pages. And you'll be able to see what's in journals you don't normally check. The hard-to-get ones. The foreign ones.

For less than $3 a week you can make *sure* you find out what's new in patient care while it's still new. Subscribe today.

©1972 ISI

Please enter my order for *Current Contents®/Clinical Practice* and invoice me later. 337

- U.S.A., Canada, & Mexico: $135 per year
- All other locations: $165 per year

☐ 2 years – save 5%
☐ 3 years – save 10%
☐ 4 years – save 15%
☐ 5 years – save 20%
☐ 6 years – save 25%

☐ Please send information on discounts available for group subscriptions.

Name_____

Organization_____

Address_____

City_____ State_____

Zip_____ Country_____

GUARANTEE: Your money refunded in full if you are not satisfied with *Current Contents/Clinical Practice* after receiving six of the weekly issues.

ISI® Institute for Scientific Information
325 Chestnut Street, Philadelphia, Pennsylvania 19106 U.S.A. Tel.: (215) 923 3300

The journal you are reading and 5000 others are regularly covered in *CURRENT CONTENTS®*.

Responsible for advertisements: L. Siegel,
D-1000 Berlin 15, Kurfürstendamm 237, Tel. (0311) 8830131, Telex: 01-85411
Springer-Verlag, Berlin · Heidelberg · New York
Printed in Germany by Wiesbadener Graphische Betriebe GmbH, D-6200 Wiesbaden

© by Springer-Verlag, Berlin Heidelberg 1973